Cargando…

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting

Background: Therapy resistance remains a serious dilemma in metastatic castration-resistant prostate cancer (mCRPC) with primary or secondary resistance frequently occurring against any given therapy. Available prognostic models for Abiraterone Acetate (AA) are specifically designed for either pre-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boegemann, Martin, Schlack, Katrin, Früchtenicht, Lena, Steinestel, Julie, Schrader, Andres Jan, Wennmann, Yvonne, Krabbe, Laura-Maria, Eminaga, Okyaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707939/ https://www.ncbi.nlm.nih.gov/pubmed/31489117 http://dx.doi.org/10.18632/oncotarget.27133

Ejemplares similares

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
por: Boegemann, Martin, et al.
Publicado: (2016)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
por: Klaile, Yvonne, et al.
Publicado: (2016)

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
por: Schlack, Katrin, et al.
Publicado: (2021)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
por: Poteska, Renata, et al.
Publicado: (2022)

Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study
por: Eminaga, Okyaz, et al.
Publicado: (2022)

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
por: Abbas, Mahmoud, et al.
Publicado: (2023)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
por: Eminaga, Okyaz, et al.
Publicado: (2023)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Clinical significance of epithelial-mesenchymal transition
por: Steinestel, Konrad, et al.
Publicado: (2014)

Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences
por: Steinestel, Julie, et al.
Publicado: (2014)

Kann Androgendeprivationstherapie eine protektive Rolle bei SARS-CoV-2-Infektionen spielen?
por: Schlack, K., et al.
Publicado: (2020)

CMDX©-based single source information system for simplified quality management and clinical research in prostate cancer
por: Eminaga, Okyaz, et al.
Publicado: (2012)

Abiraterone Acetate
Publicado: (2012)

Clinical map document based on XML (cMDX): document architecture with mapping feature for reporting and analysing prostate cancer in radical prostatectomy specimens
por: Eminaga, Okyaz, et al.
Publicado: (2010)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Conceptual Framework and Documentation Standards of Cystoscopic Media Content for Artificial Intelligence
por: Eminaga, Okyaz, et al.
Publicado: (2023)

Catheterless Long-Term Ambulatory Urodynamic Measurement Using a Novel Three-Device System
por: Wille, Sebastian, et al.
Publicado: (2014)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study
por: Boegemann, Martin, et al.
Publicado: (2019)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness
por: Schnoeller, Thomas J., et al.
Publicado: (2017)

The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma
por: Steinestel, Julie, et al.
Publicado: (2015)

Overexpression of p16(INK4a) in Urothelial Carcinoma In Situ Is a Marker for MAPK-Mediated Epithelial-Mesenchymal Transition but Is Not Related to Human Papillomavirus Infection
por: Steinestel, Julie, et al.
Publicado: (2013)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells
por: Maertens, Yvonne, et al.
Publicado: (2017)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Prognostic factors for patients treated with abiraterone
por: Alvim, Cecília M, et al.
Publicado: (2019)

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
por: Yang, Yun-Jie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8er01rm1sah5bmobn1k0uj6mdc